This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
by Ekta Bagri
PCRX and EWTX are in the spotlight this week following important regulatory and pipeline news.
BMYNegative Net Change AMGNPositive Net Change SRPTNegative Net Change PCRXNegative Net Change EWTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo
by Zacks Equity Research
Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the first-line setting.
BMYNegative Net Change FOLDNegative Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
by Zacks Equity Research
Recursion Pharmaceuticals doses the first patient in a phase I study of its investigational candidate, REC-3565, for treating B-cell lymphomas.
DVAXNegative Net Change BAYRYNegative Net Change ADMANegative Net Change RXRXNegative Net Change
biotechnology biotechs medical pharmaceuticals
PCRX Stock Soars on Exparel Patent Settlement With Generic Players
by Zacks Equity Research
Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.
DVAXNegative Net Change BAYRYNegative Net Change PCRXNegative Net Change ADMANegative Net Change
biotechnology biotechs medical pharmaceuticals
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study
by Zacks Equity Research
Rhythm Pharmaceuticals stock gains 17% on meeting goals with statistical significance in the late-stage acquired hypothalamic obesity study for setmelanotide.
DVAXNegative Net Change BAYRYNegative Net Change ADMANegative Net Change RYTMNegative Net Change
biotechnology biotechs medical pharmaceuticals
Viatris to Pay $335 Million for Settlement of Opioid-Related Claims
by Zacks Equity Research
VTRS has reached an agreement of $335 million to resolve opioid-related claims by states, local governments, and tribes against it and certain of its subsidiaries.
PFENegative Net Change BMRNNegative Net Change ADMANegative Net Change VTRSPositive Net Change
biotechnology biotechs medical pharmaceuticals
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
GILDNegative Net Change BMRNNegative Net Change FOLDNegative Net Change ADMANegative Net Change KRYSPositive Net Change
biotechnology biotechs medical pharmaceuticals
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
by Zacks Equity Research
Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.
BAYRYNegative Net Change CYTKPositive Net Change ADMANegative Net Change EWTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
BIAF Stock Surges Post Improved Earnings and Record 2024 Revenues
by Zacks Equity Research
bioAffinity witnesses record 2024 revenues, driven by CyPath Lung adoption, Medicare coverage and strategic expansion across healthcare networks.
BIAFNegative Net Change
biotechnology biotechs earnings medical
5 High ROE Stocks to Buy as Markets Face Tariff Bloodbath
by Supriyo Bose
ANET, GLW, JAZZ, AES and PPC are some of the stocks with high ROE to profit from as markets recoiled on tariff war.
GLWPositive Net Change JAZZNegative Net Change PPCNegative Net Change ANETNegative Net Change
biotechnology cloud-computing communications consumer-discretionary energy
Bayer's Vividion Initiates Dosing in Early-Stage Cancer Study
by Zacks Equity Research
BAYRY subsidiary Vividion Therapeutics doses the first patient in a phase I study on VVD-159642 to treat advanced solid tumors.
DVAXNegative Net Change GILDNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study
by Zacks Equity Research
Pacira doses the first patient in the phase II ASCEND study of PCRX-201 gene therapy for OA of the knee.
DVAXNegative Net Change BAYRYNegative Net Change PCRXNegative Net Change CORTNegative Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS Study
by Zacks Equity Research
RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.
REGNPositive Net Change RHHBYPositive Net Change GILDNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Grants Accelerated Approval to NVS Kidney Disease Drug
by Zacks Equity Research
Novartis strengthens its renal disease portfolio with accelerated approval of another drug for immunoglobulin A nephropathy.
NVSPositive Net Change GILDNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up
by Zacks Equity Research
Denali stock up as it begins rolling BLA submission with the FDA for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome.
DVAXNegative Net Change BAYRYNegative Net Change CORTNegative Net Change DNLINegative Net Change
biotechnology biotechs medical pharmaceuticals
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program
by Zacks Equity Research
Nurix stock gains as SNY expands its partnership, licensing a research program targeting a previously untreatable transcription factor for autoimmune diseases.
SNYPositive Net Change BAYRYNegative Net Change CORTNegative Net Change NRIXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More
by Ekta Bagri
CORT and AXSM are in the spotlight this week following the announcement of study data.
BMYNegative Net Change EXELNegative Net Change CORTNegative Net Change AXSMNegative Net Change
biotechnology biotechs medical pharmaceuticals
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data
by Zacks Equity Research
GRI stock plunges on the pricing of its public offering, paring the gains witnessed following positive IPF study results.
FOLDNegative Net Change ANIPPositive Net Change GRIPositive Net Change
biotechnology biotechs medical pharmaceuticals
Buy 3 Momentum Anomaly Stocks as Markets Rise Despite Tariff Threats
by Supriyo Bose
GME, WGS and APP are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
GMENegative Net Change APPNegative Net Change WGSNegative Net Change
biotechnology consumer-discretionary tech-stocks
APLS' Empaveli sNDA for 2 Rare Kidney Diseases Gets FDA Priority Tag
by Zacks Equity Research
The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.
NVSPositive Net Change BAYRYNegative Net Change CORTNegative Net Change APLSPositive Net Change
biotechnology biotechs medical pharmaceuticals
CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo
by Zacks Equity Research
BMY obtains CHMP recommendation for Opdivo for perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by surgery and adjuvant Opdivo for resectable non-small cell lung cancer.
BMYNegative Net Change FOLDNegative Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Clearway Energy (CWEN)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CWENNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Information Services Group (III) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
IIINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States
by Zacks Equity Research
The FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without inhibitors.
SNYPositive Net Change ALNYPositive Net Change BAYRYNegative Net Change CORTNegative Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
by Zacks Equity Research
The FDA approves AZN's sBLA seeking the expanded use of Imfinzi for adult patients with muscle-invasive bladder cancer.
AZNPositive Net Change DVAXNegative Net Change BAYRYNegative Net Change CORTNegative Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals